p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category
- PMID: 29168459
- PMCID: PMC5719606
- DOI: 10.4103/ijmr.IJMR_1221_15
p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category
Abstract
Background & objectives: Accurate histopathological subtyping of non-small cell lung carcinoma (NSCLC) is essential for targeted therapeutic agents. Immunohistochemistry (IHC) is helpful in identification of different tumour subtypes. In this study two marker approaches, one each for glandular and squamous cell differentiation was applied to maximize the proportion of accurately subtyped NSCLC not otherwise specified (NOS) tumours on small biopsy samples.
Methods: Two hundred and sixty three consecutive lung biopsies of primary lung carcinoma were prospectively studied. These were subtyped first morphologically and then by IHC for p40 and thyroid transcription factor-1 (TTF-1). The diagnosis of NSCLC-NOS before and after addition of IHC was evaluated. Results were correlated and validated with morphologically proven cases and matched surgical specimens.
Results: Based on morphology, only 140 of the 263 (53.2%) cases of NSCLC were characterized, whereas 123 (46.7%) were classified as NSCLC-NOS type. With addition of IHC (p40 and TTF-1), the latter category reduced to 14.4 per cent and a sum of 225 (85.5%) cases were accurately subtyped into squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma. p40 showed 100 per cent sensitivity and specificity for squamous differentiation whereas TTF-1 showed sensitivity of 85.3 per cent and specificity of 98.1 per cent. Ninety per cent correlation of morphologic subtypes was achieved with matched resected specimens.
Interpretation & conclusions: Our results showed that an approach of using only a two-antibody panel (p40 and TTF-1) might help in reduction of diagnostic category of NSCLC-NOS significantly and contribute in saving tissue for future molecular testing.
Conflict of interest statement
Figures



Comment in
-
Minimalistic immunohistochemical approach to non-small cell carcinoma of the lung in small biopsies in the context of the 2015 WHO Classification of Lung Cancer.Indian J Med Res. 2017 Jul;146(1):8-10. doi: 10.4103/ijmr.IJMR_1069_17. Indian J Med Res. 2017. PMID: 29168454 Free PMC article. No abstract available.
Similar articles
-
Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.Cancer Cytopathol. 2016 Jul;124(7):472-84. doi: 10.1002/cncy.21707. Epub 2016 Feb 29. Cancer Cytopathol. 2016. PMID: 27412420
-
Chromogenic immunohistochemical quadruplex provides accurate diagnostic differentiation of non-small cell lung cancer.Ann Diagn Pathol. 2020 Apr;45:151454. doi: 10.1016/j.anndiagpath.2019.151454. Epub 2019 Dec 14. Ann Diagn Pathol. 2020. PMID: 31923744
-
Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.J Thorac Oncol. 2010 Apr;5(4):442-7. doi: 10.1097/JTO.0b013e3181d40fac. J Thorac Oncol. 2010. PMID: 20195168
-
Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice.Int J Surg Pathol. 2013 Aug;21(4):326-36. doi: 10.1177/1066896913489346. Epub 2013 Jun 5. Int J Surg Pathol. 2013. PMID: 23740564 Review.
-
When tumor doesn't read textbook. Third case of TTF1 and p40 co-expression in the same tumour cells in a non-small cell carcinoma. A potential new entity to consider?Pathologica. 2019 Jun;111(2):58-61. doi: 10.32074/1591-951X-12-19. Pathologica. 2019. PMID: 31388196 Free PMC article. Review.
Cited by
-
Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB).Onco Targets Ther. 2019 May 29;12:4235-4244. doi: 10.2147/OTT.S199176. eCollection 2019. Onco Targets Ther. 2019. PMID: 31239702 Free PMC article.
-
Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non-small cell lung carcinoma.J Pathol Transl Med. 2021 Jul;55(4):279-288. doi: 10.4132/jptm.2021.05.10. Epub 2021 Jul 8. J Pathol Transl Med. 2021. PMID: 34233113 Free PMC article.
-
Minimalistic immunohistochemical approach to non-small cell carcinoma of the lung in small biopsies in the context of the 2015 WHO Classification of Lung Cancer.Indian J Med Res. 2017 Jul;146(1):8-10. doi: 10.4103/ijmr.IJMR_1069_17. Indian J Med Res. 2017. PMID: 29168454 Free PMC article. No abstract available.
-
Tru-cut/core Biopsy versus FNAC: Pulmonary Tumors.J Cytol. 2018 Jul-Sep;35(3):183-186. doi: 10.4103/JOC.JOC_73_18. J Cytol. 2018. PMID: 30089951 Free PMC article.
-
Coexpression of ΔNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations.JTO Clin Res Rep. 2021 Sep 2;2(11):100222. doi: 10.1016/j.jtocrr.2021.100222. eCollection 2021 Nov. JTO Clin Res Rep. 2021. PMID: 34746884 Free PMC article.
References
-
- Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452–62. - PubMed
-
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39. - PubMed
-
- Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013;137:668–84. - PMC - PubMed
-
- Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35:15–25. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources